Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating

The FDA on Tuesday approved Kala Pharmaceuticals’ Eysuvis (loteprednol etabonate ophthalmic suspension 0.25%), making it the first ocular corticosteroid for the treatment of dry eye disease and the first drug approved specifically for the short-term (up to 2 weeks) treatment of the signs and symptoms of dry eye disease.

Share . Today's Range. $6.39. Now: $7.12 $7.17. 50-Day Range.

View real-time stock prices and stock quotes for a full financial overview. In comparing Kala Pharmaceuticals, Inc. (KALA)’s stock with other industry players reveals that stock’s latest price change of +3.33% and that of -25.59% over the past 12 months is in competing position with that of Amgen Inc (AMGN) which saw its stock price raised by 2.45% in the recent trading and went through an increase of 10.06% in past 12-month trading. Recently in News on March 18, 2021, Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4). Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Kala Pharmaceuticals, Inc. (NASDAQ:KALA) posted its quarterly earnings results on Thursday, February, 25th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.46) by $0.09. The firm earned $2.24 million during the quarter, compared to analyst estimates of $2.39 million. Latest From Kala Pharmaceuticals Inc There is no recent news for this security.

2021-04-13

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Kala Pharmaceuticals, Inc. (NASDAQ:KALA) posted its quarterly earnings results on Thursday, February, 25th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.46) by $0.09. The firm earned $2.24 million during the quarter, compared to analyst estimates of $2.39 million. Latest From Kala Pharmaceuticals Inc There is no recent news for this security.

25 Feb 2021 According to a news release, the study found that Black patients with advanced heart failure were more likely to receive a left ventricular assist

Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Kala Pharmaceuticals (KALA) Northland Securities analyst Tim Chiang reiterated a Buy rating on Kala Pharmaceuticals today and set a price target of $17.00. The company’s shares closed last Monday at $8.07. According to TipRanks.com, Chiang is a 3-star analyst … Kala Pharmaceuticals' stock was trading at $7.63 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO).

Get Kala Pharmaceuticals Inc (KALA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Find the latest news for Kala Pharmaceuticals Inc Stock on our page and stay on top of the game. Kala Pharmaceuticals Announces FDA Acceptance of New Drug Application for EYSUVIS ™ for Dry Eye Disease -- FDA Sets PDUFA Goal Date of October 30, 2020 -- May 26, 2020 08:00 AM Eastern Daylight Time Kala Pharmaceuticals stock forecast & analyst price target predictions based on 4 analysts offering 12-months price targets for KALA in the last 3 months. News Smart Portfolio Markets undefined NasdaqGS:KALA Debt to Equity History April 5th 2021 How Healthy Is Kala Pharmaceuticals' Balance Sheet? The latest balance sheet data shows that Kala Pharmaceuticals had liabilities of US$22.2m due within a year, and liabilities of US$99.4m falling due after that. On the other hand, it had cash of US$154.1m and US$9.85m worth of receivables due 2021-02-24 · Kala Pharmaceuticals Inc. is expected to release its quarterly report on 05/13/2021 and quarterly earnings per share for the current quarter are estimated at -$0.46 with sales reaching $2.39M over the same period.The EPS is expected to shrink by -10.60% this year, but quarterly earnings will post 5.90% year-over-year. KALA PHARMACEUTICALS: Resubmits New Drug Application for EYSUVIS™ for Dry..
Present till 20 åring

NasdaqGS:KALA Debt to Equity History December 14th 2020 How Strong Is Kala Pharmaceuticals's Balance Sheet? According to the last reported balance sheet, Kala Pharmaceuticals had liabilities of US$19.6m due within 12 months, and liabilities of US$99.5m due beyond 12 months. 2021-04-09 · Kala Pharmaceuticals (KALA) Looks Good: Stock Adds 6% in Session by Zacks Equity Research Published on October 06,2020 Kala Pharmaceuticals (KALA) saw a big move last session, as its shares jumped Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases.

Kala Pharmaceuticals, Inc. KALA:NASDAQ. Add to Watchlist +. Trade.
Matte nationella prov gymnasiet åk 1

noltorpskyrkan alingsås program
eko ekokardiografi
innesittar sjukan
socialstyrelsen legitimation tandläkare
scania 2dehands

Kala Pharmaceuticals, Inc. (Kala) is a clinical stage pharmaceutical company focused on innovative nanoparticle-based treatments for ocular diseases affecting

Stock analysis for Kala Pharmaceuticals Inc (KALA:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company Kala Pharmaceuticals Inc (NASDAQ:KALA) · Quote · Profile · News · Charts · Forecasts · Financials · Shareholders · Competitors Find the latest Kala Pharmaceuticals, Inc. (KALA) stock quote, history, news and other vital information to help you with your stock trading and investing. Kala Pharmaceuticals Inc (NASDAQ:KALA) Share Price and News. Kala Pharmaceuticals, Inc. (Kala) is a biopharmaceutical company focused on the Kala Pharmaceuticals $KALA took a nasty hit this morning after the company disclosed mixed results for its Phase III program for the dry eye drug KPI-121.

2021-04-13

Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced KALA | Complete Kala Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Kala Pharmaceuticals Stock News module provides quick insight into current market opportunities from investing in Kala Pharmaceuticals. Use historical and current headlines to determine the investment entry and exit points. Kala Pharmaceuticals News Headlines $7.12 +0.03 (+0.42 %) (As of 03/5/2021 12:00 AM ET) Add. Compare.